A Biotech CTO on the Outsourcing Dilemma: “The Stakes Are Extremely High”

For small biotech companies, external expertise can be essential to moving drug development forward. But what happens when priorities shift, financing changes a...

Eli Lilly drops Alzheimer’s drug candidate after phase II trial

Eli Lilly is discontinuing development of its Alzheimer’s drug candidate mevidalen. The decision follows a phase II trial that failed to meet the company’s expe...

AstraZeneca unveils major cost-cutting drive

AstraZeneca beat market expectations in the third quarter. At the same time, the company announced a cost-cutting programme expected to generate annual savings ...

Sobi proposes Börje Ekholm as new chair

Börje Ekholm, the former CEO of Ericsson, has been proposed as the new chair of Sobi.

Structured Dialogue with SGS Fimko – a clearer path through MDR and IVDR

Certification under MDR and IVDR involves complex regulatory requirements and important decisions regarding documentation and the conformity assessment process....

SynAct Pharma signs first dengue drug deal

SynAct Pharma has entered into its first commercial partnership for resomelagon as a potential treatment for dengue fever.

Lilly’s triple-G drug outperforms Ozempic in head-to-head trial

Eli Lilly’s investigational drug retatrutide delivered more than twice the weight loss of rival Novo Nordisk’s Ozempic in a head-to-head phase 3 trial.

Ferring to buy IVF biotech in billion-dollar deal

Ferring has signed an agreement to acquire US biotechnology company Gameto in a deal worth up to $1.4 billion.

GRUBER aims to eliminate bottlenecks in pharmaceutical production

New welding solution aims to increase capacity and ensure quality in flip-off cap production

Danish drug candidate shows great response to two cancer types

Genmab’s hopes for petosemtamab have been boosted by positive phase II results in two cancer indications. The bispecific antibody showed promising efficacy in c...

Abbott sharpens cancer test – detects smaller traces of tumour DNA

A single tumour DNA molecule among more than a million others. That is how small a trace of cancer Abbott’s upgraded Oncodetect test is designed to detect in th...

Cell therapy scrapped after patient deaths in trial — 94 per cent of staff laid off

US biotech company Artiva Biotherapeutics is discontinuing the development of a cell therapy for autoimmune diseases and laying off 94 per cent of its workforce...

Björn Ursing: “What happens when trust in science erodes?”

Medical breakthroughs have transformed healthcare, but scientific progress alone is not enough. As misinformation spreads and trust in science comes under press...

3button group AB

AstraZeneca considers move into cancer vaccines

AstraZeneca is considering developing cancer vaccines based on mRNA technology, CEO Pascal Soriot said at a conference on Tuesday, Bloomberg News reports.

AlzeCure CEO steps down – co-founder takes over

Two multibillion-dollar deals, the company’s first profit and an oversubscribed share issue. After an eventful year, AlzeCure Pharma is changing CEO. Martin Jön...

Xbrane wins long-awaited FDA approval for eye drug biosimilar

After a long and winding road, Xbrane has now received FDA approval for Lucamzi, a biosimilar to the eye drug Lucentis.

New lung cancer combo shown to extend survival by eight months

A new drug combination extended survival by more than eight months in patients with extensive-stage small cell lung cancer, according to a late-stage clinical trial.

Enhertu wins EU approval in early breast cancer

AstraZeneca’s Enhertu is moving into earlier-stage breast cancer treatment after winning EU approval. In a phase III trial, the drug reduced the risk of invasiv...

Miris under pressure as sales fall – CEO steps down

Following a sharp decline in sales, Swedish medtech company Miris is planning a SEK 20 million rights issue. At the same time, long-serving CEO Camilla Myhre Sa...

J&J hails early prostate cancer data as “the best we have ever seen”

A new prostate cancer pill achieved a tumour response in 75 per cent of patients whose tumours could be measured in a phase I study.

Roche scores phase III win with lung cancer drug

Roche’s investigational cancer drug divarasib reduced the risk of death by 44 per cent compared with existing treatments in a phase III trial involving patients...

Early gene therapy offers hope for some ALS patients

New treatments for ALS are raising hopes among researchers. “The earlier a patient receives targeted gene therapy, the greater their chances of living longer,” ...

AstraZeneca’s ADC candidate beats expectations – new phase III data at ESMO

AstraZeneca’s experimental cancer treatment sone-ve delivered longer survival than analysts had expected in a phase III trial in advanced gastric cancer. The co...